Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prevalence of Gout and Hyperuricemia in the US

Arthritis Rheumatol; ePub 2019 Jan 7; Chen-Xu, et al

In a recent nationally representative sample of US adults, the prevalence of gout and hyperuricemia remain substantial albeit unchanged over the past decade. Despite this burden, however, only one‐third of gout patients are receiving urate‐lowering therapy (ULT). Using data from 5,467 participants from the National Health and Nutrition Examination Survey (NHANES) 2015‐2016, researchers estimated the latest prevalence of gout and hyperuricemia. During the NHANES, all participants were asked about a history of health professional‐diagnosed gout and medication use. Hyperuricemia was defined as a serum urate level >7.0 mg/dL in men and >5.7 mg/dL in women. They found:

  • The prevalence of gout was 3.9% (9.2 million) among US adults in 2015‐2016 (5.2% [5.9 million] and 2.7% [3.3 million] among men and women, respectively).
  • Mean serum urate levels were 6.0 mg/dL among men and 4.8 mg/dL among women, with hyperuricemia prevalence of 20.2% and 20.0%, respectively.
  • The prevalence of gout and hyperuricemia remained stable over the past decade.
  • The prevalence of ULT use among patients with gout was 33% during 2007‐2014 and remained stable over time.
Citation:

Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey 2007‐2016. [Published online ahead of print January 7, 2019]. Arthritis Rheumatol. doi:10.1002/art.40807.